Antithrombotic Therapy

Impact of Smoking on Long-Term Outcomes in

Patients With Atherosclerotic Vascular Disease
Treated With Aspirin or Clopidogrel
Insights From the CAPRIE Trial (Clopidogrel Versus Aspirin
in Patients at Risk of Ischemic Events)
Jos L. Ferreiro, MD,*y Deepak L. Bhatt, MD, MPH,z Masafumi Ueno, MD, PHD,*
Deborah Bauer, MS,x Dominick J. Angiolillo, MD, PHD*
Jacksonville, Florida; Barcelona, Spain; Boston, Massachusetts; and Bridgewater, New Jersey
Objectives The goal of this study was to investigate the differential efcacy of clopidogrel or aspirin monotherapy according to
smoking status in patients with atherosclerotic vascular disease.
Background Smoking enhances clopidogrel-induced platelet inhibition, which may explain the higher relative benet among
smokers observed in trials evaluating dual antiplatelet therapy. Whether smoking has an impact on clinical
outcomes in patients requiring a single antiplatelet agent remains unknown.
Methods This was a post-hoc analysis of the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trial
that compared clopidogrel and aspirin monotherapy in patients (N 19,184) with atherosclerotic vascular disease.
Results Current smokers (n 5,688) had an increased risk of ischemic events compared with never smokers (n 4,135;
hazardratio [HR]: 1.24[95%condence interval (CI): 1.08to 1.42]) andex-smokers (n 9,381; HR: 1.32[95%CI: 1.18
to 1.47]) (p <0.001). Clopidogrel was associatedwitha reduction in ischemic events among current smokers (8.3%vs.
10.8%; HR: 0.76 [95% CI: 0.64 to 0.90]), whereas no benet over aspirin was seen in the combined group of
ex-smokers/never-smoked patients (10.4% vs. 10.6%; HR: 0.99 [95% CI: 0.89 to 1.10]; p 0.01 for interaction).
Among current smokers, clopidogrel also reduced myocardial infarction, vascular death, and death from any cause
compared with aspirin. No interaction between smoking status and study treatment was observed for bleeding events.
Conclusions In a post-hoc analysis of the CAPRIE population, current smokers appeared to have enhanced benet with
clopidogrel therapy for secondary prevention compared with aspirin. These results should be considered hypothesis
generating for future prospective studies assessing the impact of specic platelet-inhibiting strategies according to
smoking status. (J Am Coll Cardiol 2014;63:76977) 2014 by the American College of Cardiology Foundation
Cigarette smoking is a potent inducer of the hepatic
cytochrome P450 (CYP) 1A2 and 2B6 isoenzymes and
can have an impact on the pharmacokinetic and
pharmacodynamic proles of drugs sharing this metabolic
pathway, including clopidogrel (14). In particular, CYP1A2
is the predominant isoenzyme responsible for the rst
From the *University of Florida College of Medicine-Jacksonville, Jacksonville,
Florida; yHeart Diseases Institute, Hospital Universitari de Bellvitge-IDIBELL,
University of Barcelona, LHospitalet de Llobregat, Barcelona, Spain; zVA Boston
Healthcare System, Brigham and Womens Hospital, and Harvard Medical School,
Boston, Massachusetts; and the xDepartment of Biostatistics, Sano, Bridgewater,
New Jersey. The CAPRIE trial was funded by Sano and Bristol-Myers Squibb. The
study sponsor had no role in the design of the present analysis. Dr. Ferreiro has received
honoraria for lectures from Eli Lilly and Company, Daiichi Sankyo, and AstraZeneca.
Dr. Bhatt has been on the advisory boards of Elsevier Practice Update Cardiology,
Medscape Cardiology, and Regado Biosciences; has been on the board of directors of
Boston VA Research Institute and the Society of Chest Pain Centers; has chaired the
American Heart Association Get With the Guidelines Science Subcommittee; has
received honoraria from the American College of Cardiology, Duke Clinical Research
Institute, Slack Publications, and WebMD; has been a senior associate editor of the
Journal of Invasive Cardiology; has been on data monitoring committees of Duke Clinical
Research Institute, Mayo Clinic, and Population Health Research Institute; has received
research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon,
Medtronic, sano-aventis, and The Medicines Company; has performed unfunded
research for FlowCo, PLx Pharma, and Takeda; has been a principal investigator on the
CHARISMA trial; has been on the steering committee of the TRILOGY-ACS trial;
and has been on the executive committee of the PEGASUS trial(s). Ms. Bauer is an
employee of sano-aventis. Dr. Angiolillo has received consulting fees or honoraria from
Bristol-Myers Squibb, sano-aventis, Eli Lilly and Company, Daiichi Sankyo, The
Medicines Company, AstraZeneca, Merck & Co., Evolva, Abbott Vascular, and PLx
Pharma; has been a consultant for Johnson & Johnson, St. Jude Medical, and Sunovion;
has received research grants (paid to his institution) from Bristol-Myers Squibb, sano-
aventis, GlaxoSmithKline, Otsuka, Eli Lilly and Company, Daiichi Sankyo, The
Medicines Company, AstraZeneca, and Evolva; and has received an Esther and King
Biomedical Research Grant. Dr. Ueno has reported that he has no relationships relevant
to the contents of this paper to disclose.
Manuscript received July 9, 2013; revised manuscript received October 7, 2013,
accepted October 15, 2013.
Journal of the American College of Cardiology Vol. 63, No. 8, 2014
2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.10.043
oxidative step in the conversion of
clopidogrel into its active metab-
olite and may therefore increase
clopidogrel biotransformation (5).
This is supported by pharma-
codynamic studies, which have
shown, with some exception (6),
that cigarette smoking enhances
clopidogrel-induced platelet in-
hibitory effects (712). These
pharmacodynamic ndings may
explain the observations from
large-scale clinical trials demon-
strating that, among clopidogrel-
treated patients, smokers have
a higher relative clinical benet compared with nonsmokers
(1319). However, to date, such a smokers paradox has
been assessed only in patients requiring dual antiplatelet
therapy (DAPT) with aspirin and clopidogrel, and whether
smoking impacts clinical outcomes in patients with athero-
sclerotic disease manifestations requiring a single antiplatelet
agent for secondary prevention of ischemic events remains
unknown.
The CAPRIE (Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events) trial is the only large-scale head-
to-head clinical investigation comparing clopidogrel versus
aspirin for secondary prevention in patients with various
atherosclerotic disease manifestations (20). The trial showed
clopidogrel to be modestly, and statistically signicantly,
more effective in reducing ischemic outcomes than aspirin,
with a favorable safety prole. The objectives of the present
analysis were 2-fold: rst, to evaluate the relationship
between smoking status and clinical outcomes in the ove-
rall CAPRIE study population; and second, to investigate
the differential effects of clopidogrel or aspirin therapy
according to smoking status.
Methods
The design, methods, and primary results of the CAPRIE
trial have been reported previously (20). In brief, CAPRIE
was a randomized, multicenter, blinded trial that compared
the efcacy of clopidogrel (75 mg once daily) and aspirin
(325 mg once daily) in reducing the risk of the outcome
event cluster of ischemic stroke, myocardial infarction (MI),
or vascular death in a population of patients with athero-
sclerotic vascular disease. The study population comprised
subgroups of patients with either recent ischemic stroke,
recent MI, or symptomatic peripheral artery disease. After
a mean follow-up of 1.91 years, clopidogrel was more
effective in reducing ischemic outcomes than aspirin (5.32%
vs. 5.83%; p 0.043). For the purpose of the present
analysis, the impact of smoking status on outcomes was
evaluated in the overall study population. In addition, the
differential treatment effect (interaction) of clopidogrel
versus aspirin according to smoking status was also
evaluated. Ischemic events were dened consistent with the
primary efcacy endpoint of the CAPRIE trial and included
the outcome event cluster of ischemic stroke, MI, or vascular
death, whichever occurred rst. In addition to the compo-
nents of the primary endpoint, a secondary efcacy endpoint
assessed was death from any cause. Smoking status was
ascertained only at a single time at the moment of enroll-
ment, and was evaluated both as collected (never smokers, ex-
smokers, and current smokers) and by combining never
smokers/ex-smokers versus current smokers. A safety
endpoint was also considered, and CAPRIE bleeding events
were dened as any bleeding disorder, as previously described
(20,21). Outcomes reported were validated by the central
validation committee of the trial.
Statistical analysis. Data are presented as numbers and
frequencies for categorical variables and as means SD for
continuous variables. All data analyses were performed on
the intention-to-treat population including all patients who
were randomized. Baseline characteristics were compared
with the chi-square test for categorical variables and analysis
of variance for continuous variables. The effect of smoking
status on ischemic events was evaluated using a Cox pro-
portional hazards model, and p values were calculated using
a log-rank test. For the overall population, the model was
stratied by qualifying condition. Tests of interaction
between smoking status and study treatment were calculated
using the Cox proportional hazards model including treat-
ment, smoking status (as a categorical variable), and the
interaction; also included in the adjusted model are the
covariates detailed in the following text. To take into account
any imbalances in baseline variables, analyses were repeated
using multivariable Cox proportional hazards model, adjust-
ing for treatment, race, diabetes, hypercholesterolemia,
congestive heart failure, cardiomegaly, atrial brillation, stable
angina, unstable angina, previous MI, transient ischemic
attack, reversible ischemic neurological decit, previous
ischemic stroke, intermittent claudication, and leg amputa-
tion (these variables were selected on the basis of a previous
multivariable analysis) (22), and also for age, sex, and body
mass index. The effect of smoking status and treatment on
bleeding disorders was evaluated using a logistic regression
model, and groups were compared using a chi-square test.
A 2-tailed p value of <0.05 was considered to indicate
a statistically signicant difference for all of the analyses per-
formed. Statistical analysis was performed using SAS version
9.2 software (SAS Institute, Cary, North Carolina).
Results
Study population. A total of 19,185 patients were
randomized in the CAPRIE trial. Smoking status was
ascertained only at the moment of enrollment and recorded
in all except 1 patient who was excluded from the present
analysis. Of the 19,184 patients evaluated, 5,668 (29.5%)
were current smokers, 9,381 (48.9%) were ex-smokers,
and 4,135 (21.6%) never smokers. Compared with
Abbreviations
and Acronyms
ACS = acute coronary
syndrome
CI = condence interval
CYP = cytochrome P450
HR = hazard ratio
DAPT = dual antiplatelet
therapy
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
Ferreiro et al. JACC Vol. 63, No. 8, 2014
Smoking Effects on Clopidogrel or Aspirin Monotherapy March 4, 2014:76977
770
never-smokers, current smokers were younger, more
frequently male, and more likely to have peripheral artery
disease, but less likely to have recent ischemic stroke as
qualifying conditions. Current smokers were also less likely
to have a history of hypertension, diabetes mellitus, atrial
brillation, stable angina, cardiomegaly, and congestive heart
failure. Baseline demographics and clinical characteristics
stratied according to smoking status (current smokers vs.
the combined group of ex-smokers and never smokers) and
treatment are shown in Table 1.
Effect of smoking status in the overall study population.
In the overall population, current and ex-smokers had
a numerically lower rate of ischemic events (primary ef-
cacy endpoint) compared with patients who never smoked:
9.5%, 9.8%, and 12.0%, respectively (p 0.30). However,
after adjustment for baseline characteristics, current
smokers had an increased risk of ischemic events compared
with patients who never smoked (hazard ratio [HR]: 1.24
[95% condence interval (CI): 1.08 to 1.42]) and to ex-
smokers (HR: 1.32 [95% CI: 1.18 to 1.47]), achieving
statistical signicance (p < 0.001). Both unadjusted and
adjusted HRs for the overall population and the study
subgroups (patients with recent ischemic stroke, recent MI,
or symptomatic peripheral artery disease) are reported
in Table 2.
Similar results were obtained when analyzing smoking
status as a dichotomous variable. Current smokers had
a numerically lower rate of the primary efcacy endpoint
compared with ex-smokers/never-smoked patients, which
did not reach statistical signicance (9.5% vs. 10.5%, HR:
0.99 [95% CI: 0.89 to 1.09]; p 0.82). However, in the
adjusted model, current smokers had an enhanced risk of
ischemic outcomes compared with the combined group of
ex-smokers/never-smoked subjects (HR: 1.30 [95% CI: 1.17
to 1.44]; p < 0.001).
Bleeding disorders occurred in 8.6% of current smokers,
9.7% of ex-smokers, and 9.1% of never-smoked patients
(p 0.07). When evaluating smoking status as a dichoto-
mous variable, current smokers had a lower rate of bleeding
events compared with ex-smokers/never-smoked subjects
(8.6% vs. 9.6%; odds ratio [OR]: 0.89 [95% CI: 0.80 to
0.99]; p 0.04). In the adjusted model, the ratio was
inverted, indicating that current smokers had a signicantly
increased risk of bleeding events compared with patients
who had never smoked (OR: 1.23 [95% CI: 1.04 to 1.46];
p 0.02) and similar when compared with ex-smokers
(OR: 0.93 [95% CI: 0.83 to 1.05]; p 0.25). No differ-
ence was seen between current smokers and the combined
group of ex-smokers/never-smoked patients (OR: 1.01
[95% CI: 0.90 to 1.13]; p 0.93).
Table 1 Baseline Demographic Data and Clinical Characteristics Stratied According to Smoking Status and Treatment
Aspirin
Current Smokers
(n 2,860)
Clopidogrel
Current Smokers
(n 2,808) p Value
Aspirin
Ex/Never Smokers
(n 6,726)
Clopidogrel
Ex/Never Smokers
(n 6,726) p Value
Age, yrs 58.6 10.9 58.3 10.8 0.3933 64.2 10.7 64.1 10.8 0.8294
Male 2,174 (76.0) 2,145 (76.4) 0.7404 4,731 (70.3) 4,804 (70.8) 0.5992
BMI, kg/m
2
25.9 4.4 25.9 4.3 0.8158 26.7 4.4 26.7 4.4 0.7273
Race 0.5564 0.0025
Caucasian 2,718 (95.0) 2,665 (94.9) 6,378 (94.8) 6,415 (94.5)
Black 92 (3.2) 81 (2.9) 169 (2.5) 210 (3.1)
Asian 13 (0.5) 15 (0.5) 65 (1.0) 35 (0.5)
Other 37 (1.3) 47 (1.7) 114 (1.7) 130 (1.9)
Risk factors
Hypertension 1,225 (42.8) 1,187 (42.3) 0.6698 3,679 (54.7) 3,793 (55.9) 0.1738
Diabetes mellitus 451 (15.8) 425 (15.1) 0.5092 1,510 (22.5) 1,494 (22.0) 0.5318
Dyslipidemia 1,132 (39.6) 1,156 (41.2) 0.2232 2,845 (42.3) 2,770 (40.8) 0.0762
Medical history
Stable angina 510 (17.8) 525 (18.7) 0.3997 1,561 (23.2) 1,575 (23.2) 0.9862
Unstable angina 207 (7.2) 208 (7.4) 0.8063 617 (9.2) 629 (9.3) 0.8561
Atrial brillation 56 (2.0) 87 (3.1) 0.0062 337 (5.0) 331 (4.9) 0.7161
Cardiac surgery 142 (5.0) 157 (5.6) 0.2917 566 (8.4) 623 (9.2) 0.1188
Other cardiac arrhythmia 242 (8.5) 246 (8.8) 0.6881 734 (10.9) 821 (12.1) 0.0318
Cardiac valve disease 79 (2.8) 81 (2.9) 0.7809 282 (4.2) 305 (4.5) 0.3935
Cardiomegaly 83 (2.9) 108 (3.8) 0.0489 333 (5.0) 361 (5.3) 0.3355
Congestive heart failure 110 (3.8) 116 (4.1) 0.5836 414 (6.2) 433 (6.4) 0.5947
Qualifying condition 0.8084 0.8961
Ischemic stroke 719 (25.1) 708 (25.2) 2,479 (36.9) 2,525 (37.2)
Peripheral artery disease 1,235 (43.2) 1,232 (43.9) 1,994 (29.6) 1,991 (29.3)
Myocardial infarction 906 (31.7) 868 (30.9) 2,253 (33.5) 2,274 (33.5)
Values are mean SD or n (%).
BMI body mass index.
JACC Vol. 63, No. 8, 2014 Ferreiro et al.
March 4, 2014:76977 Smoking Effects on Clopidogrel or Aspirin Monotherapy
771
Effect of smoking status on study treatment: clopidogrel
versus aspirin. In aspirin-treated patients, the unadjusted
analysis showed no signicant difference according to
smoking status (current smokers vs. ex-smokers/never-
smoked subjects) in the overall population (10.8% vs.
10.6%, HR: 1.11 [95% CI: 0.97 to 1.27]; p 0.14).
However, in the adjusted model, current smokers had
a higher risk of ischemic outcomes (HR: 1.39 [95% CI: 1.20
to 1.60]; p < 0.001), an effect that was consistent among all
qualifying conditions. Similarly, the impact on ischemic
outcomes in clopidogrel-treated patients was not observed
in the unadjusted model (8.3% vs. 10.4%, HR: 0.87 [95%
CI: 0.75 to 1.01]; p 0.07), but it reached signicance
in the adjusted analysis (HR: 1.19 [95% CI: 1.02 to 1.39];
p 0.03).
A signicant interaction between study treatment and
smoking status was found (p 0.01 for interaction) when
evaluated as a dichotomous variable (current smokers vs.
ex-smokers/never-smoked patients). In particular, clopidogrel-
treated patients had no reduction in the incidence of the
primary efcacy outcome compared with aspirin-treated
patients in the combined group of ex-smokers/never-
smoked patients (10.4% vs. 10.6%; HR: 0.99 [95% CI:
0.89 to 1.10]; p 0.73), whereas patients treated with
clopidogrel in the current smoker group had a signicantly
lower rate of ischemic events (8.3% vs. 10.8%; HR: 0.76
[95% CI: 0.64 to 0.90]; p 0.001) than aspirin-treated
patients (Fig. 1). This trend toward a lower risk of
ischemic events among clopidogrel-treated subjects was
observed in all qualifying conditions (recent ischemic stroke:
14.0% vs. 16.1%, HR: 0.88 [95% CI: 0.67 to 1.16]; recent
MI: 7.4% vs. 8.7%, HR: 0.88 [95% CI: 0.63 to 1.22];
and peripheral artery disease: 5.7% vs. 9.1%, HR: 0.60
[95% CI: 0.44 to 0.81]). The benet of the clopidogrel-
treated current smokers subgroup compared with the
other 3 subgroups (clopidogrel-treated ex-smokers/never
smoked, aspirin-treated current smokers, and aspirin-
treated ex-smokers/never smoked) was observed during the
entire study follow-up (Fig. 2A). Among current smokers,
in addition to the benet observed in the combined primary
efcacy endpoint, clopidogrel was associated with a reduc-
tion in MI, vascular death, or death from any cause
compared with aspirin, with the interaction mainly due to
the difference in the rates of vascular death (Fig. 3).
When evaluating smoking status as a variable with
3 categories (current smokers, ex-smokers, and never
smokers), a signicant interaction (p < 0.01) with study
treatment for the primary efcacy endpoint was observed
in the overall population due to no observed efcacy in
ex-smokers (clopidogrel vs. aspirin: 8.3% vs. 10.8% in current
smokers, HR: 0.76 [95% CI: 0.64 to 0.90], p 0.002;
10.1% vs. 9.5% in ex-smokers, HR: 1.10 [95% CI: 0.97 to
1.26], p 0.14; 10.9% vs. 13.1% in patients who never
smoked, HR: 0.79 [95% CI: 0.66 to 0.94]; p < 0.01).
No interaction between smoking status and study treat-
ment was observed for bleeding events when considering
the variable smoking status with 3 categories (current
smokers, ex-smokers, and never smokers) or dichotomous
(current smokers vs. ex-smokers/never-smoked patients):
p 0.35 and p 0.73 for interaction, respectively. The
incidence of bleeding events in the 4 subgroups of subjects
evaluated according to smoking status and treatment
(clopidogrel-treated current smokers, clopidogrel-treated
ex-smokers/never smokers, aspirin-treated current smokers,
and aspirin-treated ex-smokers/never smokers) was similar,
as illustrated in Figure 2B.
Discussion
The present analysis of the CAPRIE trial showed that: 1)
current smokers, despite being younger and with fewer
comorbidities, presented in the adjusted model with an
Table 2
Summary of Patients With Ischemic Events and Unadjusted and Adjusted HRs for the Primary Efcacy Endpoint
According to Smoking Status
Never Smokers
(n 4,135)
Ex-Smokers
(n 9,381)
Current Smokers
(n 5,668)
Unadjusted HR
(95% CI)
Adjusted HR*
(95% CI)
Overall (N 19,184) 496 (12.0) 921 (9.8) 541 (9.5) 0.92 (0.821.03) 0.94 (0.831.06)
0.93 (0.821.06) 1.24 (1.081.42)
1.02 (0.911.13) 1.32 (1.181.47)
Ischemic stroke (n 6,431) 296 (13.4) 383 (13.7) 215 (15.1) 1.01 (0.871.18) 0.98 (0.831.15)
1.11 (0.931.32) 1.34 (1.101.62)
1.09 (0.931.29) 1.37 (1.151.63)
Myocardial infarction (n 6,301) 139 (10.3) 290 (9.1) 143 (8.1) 0.87 (0.711.07) 1.00 (0.811.24)
0.78 (0.620.98) 1.18 (0.911.52)
0.89 (0.731.09) 1.18 (0.961.45)
Peripheral artery disease (n 6,452) 61 (10.6) 248 (7.3) 183 (7.4) 0.65 (0.490.86) 0.71 (0.530.96)
0.68 (0.510.91) 1.02 (0.741.41)
1.05 (0.871.28) 1.43 (1.181.75)
Values are n (%). In the Unadjusted and Adjusted HR columns, the rst hazard ratio (HR) is for ex-smokers versus never smokers, the second hazard ratio is for current smokers versus never smokers, and the
third hazard ratio is for current smokers versus ex-smokers. *Model adjusted for treatment, age, sex, body mass index, race, diabetes, hypercholesterolemia, congestive heart failure, cardiomegaly, atrial
brillation, stable angina, unstable angina, previous myocardial infarction, transient ischemic attack, reversible ischemic neurological decit, previous ischemic stroke, intermittent claudication, and leg
amputation.
CI condence interval.
Ferreiro et al. JACC Vol. 63, No. 8, 2014
Smoking Effects on Clopidogrel or Aspirin Monotherapy March 4, 2014:76977
772
increased risk of long-term ischemic events; 2) among
current smokers, clopidogrel therapy achieved a reduction in
ischemic events, whereas no difference between aspirin and
clopidogrel treatment was observed in the combined group
of ex-smokers/never smokers; and 3) no signicant inter-
action was seen between treatment and smoking habit for
bleeding events. Although smoking cessation represents the
optimal healthcare goal, these ndings suggest that clopi-
dogrel may offer greater ischemic protection and potentially
be preferred over aspirin for smokers with stable athero-
sclerotic vascular disease and requiring a single antiplatelet
drug regimen. Indeed, the availability of clopidogrel in
a generic formulation with contained costs, which in the past
had limited its more broad-scale use, makes this an
appealing treatment option in subsets of patients in which
clopidogrel may improve outcomes when compared with
aspirin.
Smoking is an established major risk factor for all-cause
and cardiovascular mortality, as well as for ischemic and
bleeding outcomes, and smoking cessation is a Class I
recommendation (Level of Evidence: A) for secondary
prevention in patients with atherosclerotic vascular disease
(23). Although the optimal healthcare goal is to reinforce the
importance of smoking cessation, this is not achieved in
many patients, as also reected by the slowing in the decline
in adult smoking (24). These observations underscore the
importance of dening more-effective secondary prevention
treatment strategies for patients who continue to smoke and
thus remain at increased risk for ischemic recurrences.
DAPT with aspirin and clopidogrel represents the most
broadly utilized treatment for patients presenting with an
acute coronary syndrome (ACS) or undergoing percutaneous
coronary intervention (PCI). Despite having increased
rates of adverse events, smokers have been shown to have
a higher relative clinical benet of DAPT compared with
nonsmokers (1319). Importantly, for patients requiring
DAPT, more-potent antiplatelet treatment strategies (e.g.,
prasugrel, ticagrelor) are currently available, and may
therefore be considered in patients requiring more effective
platelet blockade because of their high-risk prole (25,26).
These agents have a more favorable pharmacokinetic and
pharmacodynamic prole compared with clopidogrel, and
outcomes of patients treated with these agents are not
affected by smoking (6,27). This is supported also in the
recently reported PARADOX (Inuence of Smoking Status
on Prasugrel and Clopidogrel Treated Subjects Taking
Aspirin and Having Stable Coronary Artery Disease) trial,
which showed that the antiplatelet efcacy of clopidogrel is
reduced in nonsmokers, whereas prasugrel-mediated platelet
inhibition is not inuenced by smoking status (28). In
addition, in the large-scale TRILOGY ACS (Targeted
Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes) clinical trial
that randomized ACS patients not undergoing revasculari-
zation to long-term therapy with prasugrel versus clopi-
dogrel (29), there was a signicant interaction between
treatment and smoking, showing almost a 50% relative
reduction in ischemic events with prasugrel versus clopi-
dogrel treatment among smokers. Because smoking had no
signicant impact on prasugrel efcacy, this differential
effect might be due to an increased risk of adverse outcomes
of smokers compared with nonsmokers among clopidogrel-
treated patients (30). Because smokers have an increased
density of P2Y
12
receptors on the platelet surface (31),
Figure 1 Ischemic Events According to Smoking Status and Study Treatment
Percentage of patients with ischemic events according to smoking status (never/ex-smokers vs. current smokers) and study treatment (aspirin vs. clopidogrel) is shown.
HR hazard ratio.
JACC Vol. 63, No. 8, 2014 Ferreiro et al.
March 4, 2014:76977 Smoking Effects on Clopidogrel or Aspirin Monotherapy
773
this may also have played a role in the observed benet
of prasugrel over clopidogrel in this subgroup analysis (30).
Most patients with atherosclerotic manifestations do not
have a clinical indication to be on DAPT, which is
generally recommended for up to 1 year in the settings of
ACS and PCI, and the use of DAPT has been shown to
be potentially harmful outside of these clinical presenta-
tions (32). Therefore, dening the optimal treatment for
patients requiring only a single antiplatelet agent, either
aspirin or clopidogrel, for secondary prevention of ischemic
events is of paramount importance. Overall, the results of
the present investigation may have practical implications
Figure 2 Kaplan-Meier Curves of Ischemic and Bleeding Events Stratied According to Smoking Status and Study Treatment
(A) The cumulative ischemic event rates, expressed as percentages, according to smoking status (never [Nvr]/ex-smokers [Ex] and current [Cur] smokers) and study treatment
(aspirin [ASA] and clopidogrel [Clop]). (B) The cumulative bleeding event rate, expressed as percentages, according to smoking status (never/ex-smokers and current smokers)
and study treatment (aspirin and clopidogrel).
Ferreiro et al. JACC Vol. 63, No. 8, 2014
Smoking Effects on Clopidogrel or Aspirin Monotherapy March 4, 2014:76977
774
for current clinical practice. In particular, one might
consider recommending clopidogrel therapy for smokers
and aspirin for nonsmokers when a single antiplatelet agent
is required in patients with atherothrombotic diseases, such
as for secondary prevention in patients with peripheral
artery disease, a prior stroke, or in those with ACS or PCI
after completing 1 year of DAPT. Further, the use of
clopidogrel must be also considered in nonsmoking,
aspirin-intolerant patients, because no other option (e.g.,
prasugrel, ticagrelor) has been tested for monotherapy. If
P2Y
12
blockade is clinically superior to aspirin, as it
appears to be in clopidogrel-treated smokers, the ndings
of this study also pose the question of whether mono-
therapy with the more potent P2Y
12
antagonist prasugrel
or ticagrelor would be even superior to both aspirin and
clopidogrel. This concept is currently being evaluated in
the GLOBAL LEADERS (A Clinical Study Comparing
Two Forms of Anti-platelet Therapy After Stent
Implantation) trial (NCT01813435) that aims to enroll
approximately 16,000 patients from an all-comers pop-
ulation undergoing PCI with a drug-eluting stent with an
abluminally-coated biodegradable polymer. Patients will be
followed for 2 years after being randomized to either: 1)
a study treatment strategy of 1 month of aspirin plus
ticagrelor followed by 23 months of ticagrelor mono-
therapy; or 2) a reference treatment strategy of 12 months
of DAPT (aspirin plus ticagrelor for ACS patients; aspirin
plus clopidogrel for elective patients) followed by 12
months of aspirin monotherapy.
CAPRIE is the only large-scale investigation to our
knowledge to assess differences in safety and efcacy
between aspirin and clopidogrel monotherapy for secondary
prevention of ischemic events in patients with atherosclerotic
disease manifestations. Although clopidogrel was associated
with a favorable safety prole, including bleeding and
nonbleeding side effects, and reduced ischemic event rates
compared with aspirin, a nding that was of even greater
magnitude in higher-risk subgroups, aspirin has represented
the mainstay of treatment for these patients (20,33). Indeed,
costs may have contributed to this practice pattern, given
that clopidogrel has only recently become available in
a generic formulation. Importantly, the ndings of the
present investigation also suggest that the benet of clopi-
dogrel over aspirin can be attributed in part to its effect
among smokers. The greater magnitude of benet of
clopidogrel among smokers (smokers paradox) is likely
attributed to the more effective platelet inhibition that is
achieved in these patients, as demonstrated by the higher
rates of reperfusion observed in patients with ST-segment
elevation MI undergoing routine angiography (13), and
also consistently shown in various pharmacodynamic inves-
tigations (1316). However, this greater effect of clopidogrel
among smokers must not be overstated, and it must not be
concluded from the results of our study that clopidogrel is
Figure 3 HRs for Cardiovascular Events
Hazard ratios (HRs) and 95% condence intervals (CIs) for cardiovascular events in clopidogrel-versus aspirin-treated patients (adjusted model) are shown. ASA aspirin;
MI myocardial infarction.
JACC Vol. 63, No. 8, 2014 Ferreiro et al.
March 4, 2014:76977 Smoking Effects on Clopidogrel or Aspirin Monotherapy
775
not effective in patients that do not currently smoke. In fact,
in the present analysis, patients who were never smokers
(when not combined with ex-smokers) also obtained
a benet from clopidogrel therapy compared with aspirin.
Pharmacodynamic studies have shown a broad range in the
interindividual response prole among clopidogrel-treated
patients, and those who have high on-treatment platelet
reactivity have an increased risk of ischemic recurrences,
including stent thrombosis (34,35). Cigarette smoking is
a strong inducer of the activity of CYP1A2 and CYP2B6,
which are involved in the hepatic transformation of clopi-
dogrel (1,2), thus leading to an enhanced production of
its active metabolite (5). The greater clopidogrel-induced
platelet inhibition observed in current smokers compared
with nonsmokers was rst demonstrated by Bliden et al. (7)
in a cohort of patients on DAPT undergoing elective coro-
nary stenting, and later conrmed in other settings (8,9),
notably showing a doseresponse effect according to the
intensity of smoking (9). Although some studies have not
found an association between smoking and clopidogrel ef-
cacy (6), a causal relationship between smoking and degree
of clopidogrel-induced antiplatelet effects is also supported
by the observation that the enhanced platelet inhibitory
effects among smokers diminished with smoking discontin-
uation (36). Other studies suggest that this benet may
occur in patients more likely to have reduced clopidogrel
response, based on clinical presentation (e.g., diabetic status)
or CYP1A2 polymorphisms (9,37).
In addition to a more favorable metabolism of clopidogrel
due to enhanced CYP enzymatic activity, other mechanisms
may contribute to the benet among smokers. Nicotine has
been shown to be associated with higher platelet P2Y
12
receptor expression in platelet lysates compared with that of
nonsmokers (31). Therefore, it may be hypothesized that
the benet of clopidogrel over aspirin may be due to the
fact that smokers have higher platelet surface P2Y
12
density,
contributing to their higher risk for recurrent events, which
can be suppressed by clopidogrel, but not by aspirin (31).
Also, smoking has been associated with less biological
efcacy of aspirin, also coined aspirin resistance, as
determined by increased platelet reactivity and incomplete
inhibition of thromboxane biosynthesis compared with
that of smokers (38). However, in the CHARISMA (Clo-
pidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management and Avoidance) trial, randomi-
zation to clopidogrel versus placebo did not reduce the hazard
of cardiovascular events in low-risk aspirin-treated patients
in the highest quartile of urinary 11-dehydro-thromboxane
B2 levels (39).
Study limitations. The major limitation is that the present
study is a post-hoc subgroup analysis of a large-scale clinical
trial and, thus, there is potential for bias because the study
was not designed and powered for subgroup analyses.
Indeed, the more subgroup analyses of a given trial that are
performed, the more likely that a positive nding in 1 of
them may be due to the play of chance. Therefore, the
results observed in the present investigation must be
considered only hypothesis generating. For instance, the fact
that the benet observed for clopidogrel therapy among
current smokers mainly depended on the individual
endpoint of vascular death, whereas no relevant interaction
was seen for stroke or MI, urges caution with the conclu-
sions derived regarding a different clopidogrel benet
depending on smoking status. This is also in line with the
observation from the present analysis that patients who were
never smokers (when not combined with ex-smokers) also
obtained a benet from clopidogrel therapy compared with
aspirin. Further, the CAPRIE trial was published in 1996,
which may limit the clinical signicance of the present
analysis because clinical practice has evolved and differs from
standards used when patients were recruited in this trial.
However, this is the rst study to assess the impact of
smoking in patients requiring single antiplatelet therapy for
secondary prevention of ischemic events, which in addition
to the consistent ndings with DAPT trials (1316) and
the plausible biological explanations based on a multitude
of pharmacodynamic studies, is reassuring (712). Finally,
smoking status was based on a single determination at
enrollment that may have changed over the study period.
However, misclassication of smoking status would more
likely have attenuated the strength of the association
between current smokers and adverse outcomes.
Conclusions
In a population of patients with stable atherosclerotic
vascular disease, smoking is associated with an increased
risk of adverse ischemic outcomes, both in aspirin- and
clopidogrel-treated patients. Current smokers treated with
clopidogrel for the secondary prevention of ischemic
recurrences had a greater reduction in events compared with
those treated with aspirin, whereas no clear benet of clo-
pidogrel over aspirin was seen in the combined group of
ex-smokers/never smokers. Although smoking cessation
represents the optimal healthcare goal, these ndings sug-
gest that clopidogrel may offer greater ischemic protection
and potentially be preferred over aspirin for smokers with
stable atherosclerotic vascular disease requiring a single
antiplatelet drug.
Reprint requests and correspondence: Dr. Dominick J. Angio-
lillo, University of Florida College of Medicine-Jacksonville, 655
West 8th Street, Jacksonville, Florida, 32209. E-mail: dominick.
[email protected].
REFERENCES
1. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity
on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:
17884.
2. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An
update. Clin Pharmacokinet 1999;36:42538.
Ferreiro et al. JACC Vol. 63, No. 8, 2014
Smoking Effects on Clopidogrel or Aspirin Monotherapy March 4, 2014:76977
776
3. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions.
J Am Coll Cardiol 2011;57:125163.
4. Washio I, Maeda M, Sugiura C, et al. Cigarette smoke extract induces
CYP2B6 through constitutive androstane receptor in hepatocytes.
Drug Metab Dispos 2011;39:13.
5. Yousef AM, Arafat T, Bulatova NR, Al-Zumyli R. Smoking behaviour
modulates pharmacokinetics of orally administered clopidogrel. J Clin
Pharm Ther 2008;33:43949.
6. Hochholzer W, Trenk D, Mega JL, et al. Impact of smoking on
antiplatelet effect of clopidogrel and prasugrel after loading dose and on
maintenance therapy. Am Heart J 2011;162:51826.e5.
7. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette
smoking with enhanced platelet inhibition by clopidogrel. J Am Coll
Cardiol 2008;52:5313.
8. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S,
Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition
in patients receiving dual antiplatelet therapy. Thromb Res 2009;124:
58891.
9. Ueno M, Ferreiro JL, Desai B, et al. Cigarette smoking is associated
with a dose-response effect in clopidogrel-treated patients with diabetes
mellitus and coronary artery disease: results of a pharmacodynamic
study. J Am Coll Cardiol Intv 2012;5:293300.
10. Motovska Z, Widimsky P, Petr R, et al. Factors inuencing clopidogrel
efcacy in patients with stable coronary artery disease undergoing
elective percutaneous coronary intervention: statins advantage and the
smoking paradox. J Cardiovasc Pharmacol 2009;53:36872.
11. Cho JH, Jeong YH, Ahn YJ, et al. The impact of smoking on post-
clopidogrel platelet reactivity in patients with acute myocardial infarc-
tion. Korean Circ J 2010;40:11924.
12. Jeong YH, Cho JH, Kang MK, et al. Smoking at least 10 cigarettes
per day increases platelet inhibition by clopidogrel in patients with
ST-segment-elevation myocardial infarction. Thromb Res 2010;126:
e3348.
13. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction
between cigarette smoking and clinical benet of clopidogrel. J Am
Coll Cardiol 2009;53:12738.
14. Salek FS. Relationship between clopidogrel and cigarette smoking
status in patients with acute coronary syndromes without ST-segment
elevation myocardial infarction (abstr). Pharmacotherapy 2010;30:154e.
15. Saraff KY, Steinhubl SR, Hsu AP, Topol EJ. Smoking inuences the
effectiveness of dual antiplatelet therapy on long-term outcomes
following percutaneous coronary intervention (abstr). J Am Coll
Cardiol 2006;47:36B.
16. Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and
mortality in patients with established cardiovascular disease. Circulation
2009;120:233744.
17. Gurbel PA, Nolin TD, Tantry US. Clopidogrel efcacy and cigarette
smoking status. JAMA 2012;307:24956.
18. Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J.
Effect of smoking on comparative efcacy of antiplatelet agents:
systematic review, meta-analysis, and indirect comparison. BMJ 2013;
347:f5307.
19. Zhao ZG, Chen M, Peng Y, et al. The impact of smoking on clinical
efcacy and pharmacodynamic effects of clopidogrel: a systematic
review and meta-analysis. Heart 2014;100:1929.
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopi-
dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet 1996;348:132939.
21. Harker LA, Boissel JP, Pilgrim AJ, Gent M, CAPRIE Steering
Committee and Investigators. Comparative safety and tolerability of
clopidogrel and aspirin: results from CAPRIE. Drug Saf 1999;21:
32535.
22. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, Clopidogrel
Versus Aspirin in Patients at Risk of Ischemic Events Investigators.
Benet of clopidogrel over aspirin is amplied in patients with a history
of ischemic events. Stroke 2004;35:52832.
23. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary
prevention and risk reduction therapy for patients with coronary and
other atherosclerotic vascular disease: 2011 update: a guideline from the
American Heart Association and American College of Cardiology
Foundation. J Am Coll Cardiol 2011;58:243246.
24. Koh HK, Sebelius KG. Ending the tobacco epidemic. JAMA 2012;
308:7678.
25. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clo-
pidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357:200115.
26. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel
in patients with acute coronary syndromes. N Engl J Med 2009;361:
104557.
27. Cornel JH, Becker RC, Goodman SG, et al. Prior smoking status,
clinical outcomes, and the comparison of ticagrelor with clopidogrel
in acute coronary syndromesdinsights from the PLATelet inhibition
and patient Outcomes (PLATO) trial. Am Heart J 2012;164:
33442.
28. Gurbel PA, Bliden KP, Logan DK, et al. The inuence of smoking
status on the pharmacodynamics of prasugrel and clopidogrel: the
PARADOX study. J Am Coll Cardiol 2013;62:50512.
29. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel
for acute coronary syndromes without revascularization. N Engl J Med
2012;367:1297309.
30. Cornel JH, Ohman M, Neely B, et al. Impact of smoking status on
clinical outcomes with prasugrel versus clopidogrel in patients with
acute coronary syndromes managed without revascularization: insights
from the TRILOGY ACS trial (abstr). J Am Coll Cardiol 2013;
61 Suppl 10:
31. Shanker G, Kontos JL, Eckman DM, et al. Nicotine upregulates the
expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb
Thrombolysis 2006;22:21320.
32. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus
aspirin alone for the prevention of atherothrombotic events. N Engl J
Med 2006;354:170617.
33. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ.
Amplied benet of clopidogrel versus aspirin in patients with diabetes
mellitus. Am J Cardiol 2002;90:6258.
34. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in
individual responsiveness to clopidogrel: clinical implications,
management, and future perspectives. J Am Coll Cardiol 2007;49:
150516.
35. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current
status and future directions. Thromb Haemost 2009;102:714.
36. Park KW, Kang SH, Kang J, et al. Enhanced clopidogrel response in
smokers is reversed after discontinuation as assessed by VerifyNow
assay: additional evidence for the concept of smokers paradox. Heart
2012;98:10006.
37. Park KW, Park JJ, Jeon KH, et al. Enhanced clopidogrel responsiveness
in smokers: smokers paradox is dependent on cytochrome P450
CYP1A2 status. Arterioscler Thromb Vasc Biol 2011;31:66571.
38. Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin
efcacy in patients with stable coronary artery disease. Thromb Hae-
most 2011;105:33644.
39. Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of
thromboxane biosynthesis by acetylsalicylic acid: determinants and
effect on cardiovascular risk. Circulation 2008;118:170512.
Key Words: antiplatelet agents
-
clopidogrel
-
smoking
-
smoking paradox.
JACC Vol. 63, No. 8, 2014 Ferreiro et al.
March 4, 2014:76977 Smoking Effects on Clopidogrel or Aspirin Monotherapy
777
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.